High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Mo:re is focused on transforming organoid-based drug development through its innovative lab platform that automates cell culture workflows. The company has developed a 3D cell robotic platform aimed at enhancing medical research by standardizing protocols and facilitating remote operations. Mo:re specializes in areas such as cell therapy, drug development, and disease modeling, enabling researchers to scale experiments effectively while maintaining high standards of traceability and quality.
Hema.to
Seed Round in 2025
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
Refoxy Pharma
Seed Round in 2024
Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. The company researches FOXO proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.
Doctorflix
Seed Round in 2024
Doctorflix is a medical education platform designed to enhance the professional development of healthcare providers worldwide. It offers a comprehensive array of resources, including on-demand videos, live events, articles, and podcasts, aimed at transforming theoretical knowledge into practical applications. The platform seeks to simplify and democratize access to medical knowledge by connecting doctors, hospitals, and pharmaceutical companies, thereby facilitating an efficient exchange of information. With a strong foundation in both medical and technological expertise, Doctorflix is dedicated to advancing the education of medical professionals, ensuring they stay informed about the latest treatment methods and practices.
Sedivention
Pre Seed Round in 2024
Sedivention is a medical technology company specializing in the development of minimally invasive devices for obesity treatment. Their flagship product is a cryo catheter that, in a single, brief procedure akin to a gastroscopy, freezes and ablates the gastric branches of the vagus nerve, reducing hunger and promoting weight loss. This outpatient procedure offers a less invasive alternative to traditional obesity treatments.
Nuuron
Seed Round in 2024
Nuuron is a neurotechnology company specializing in the development of a non-invasive, photonic neurostimulation device called the Memory-Pacemaker. This device is designed to help Alzheimer's patients store and retrieve memories by using the retina as a computer-brain interface and employing ultra-high frequency, digital photonic stimuli to activate the memory center.
Aignostics
Series B in 2024
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
BIOVOX
Seed Round in 2024
BIOVOX is a company that specializes in the development of biodegradable plastic components aimed at various industries, including medicine, hygiene, and food. By utilizing renewable, fully degradable, and recyclable raw materials, BIOVOX produces high-quality bioplastic compounds that offer an alternative to conventional plastics. The company's products are designed to help reduce carbon dioxide emissions, promoting an environmentally sustainable approach to materials in healthcare and beyond. Through its innovations, BIOVOX sets a standard in the sustainable healthcare market, encouraging clients to adopt more eco-friendly practices.
Symphera
Seed Round in 2024
Symphera is a developer of an all-in-one surgical system focused on enhancing the efficiency of minimally invasive procedures. The company offers a laparoscopic surgical tool that aims to simplify and accelerate surgeries, thereby providing healthcare professionals with improved control, autonomy, safety, and operational efficiency. By innovating in the surgical field, Symphera seeks to transform the way minimally invasive surgeries are conducted, ultimately benefiting both medical practitioners and patients.
IRUBIS
Seed Round in 2024
IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.
HepaRegenix
Series C in 2024
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.
SciRhom
Series A in 2024
SciRhom GmbH is a biotech company focused on the preclinical and early clinical development of novel biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Founded in 2016 through collaboration between academic and industry scientists with expertise in antibody development, SciRhom leverages extensive research and a network of specialists to advance its therapeutic offerings. The company develops therapeutic antibodies targeting iRhom2, a significant modulator of key pro-inflammatory signaling pathways, including TNF-alpha. This approach seeks to enhance treatment options for patients suffering from severe autoimmune conditions, particularly those affecting the skin and intestinal barriers.
CustomSurg
Seed Round in 2024
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
RAYDIAX
Seed Round in 2023
RAYDIAX specializes in the development of advanced therapy-assist CT systems aimed at enhancing the safety and effectiveness of minimally invasive medical interventions. The company’s imaging solutions integrate both 2D and 3D X-ray live imaging with a sophisticated navigation system, allowing healthcare providers to perform precise and efficient tumor interventions. By focusing on reducing the risk of postoperative complications, RAYDIAX's technology contributes to shorter hospital stays and faster recovery times for patients. The company's commitment to improving the quality of care supports clinicians in delivering better outcomes in cancer therapy.
Inovedis
Series A in 2023
Inovedis specializes in medical technology, focusing on innovative solutions that enhance patient care while reducing time and costs in the healthcare sector. The company has developed a surgical device aimed at treating shoulder-based injuries more effectively. This device facilitates anatomical reconstruction of the physiological tendon-bone connection, helping to maintain metabolic function. By leveraging advanced technology, Inovedis enables surgeons to minimize the complexity of surgical techniques, ultimately providing greater relief to patients.
Kranus Health
Series A in 2023
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
InContAlert
Pre Seed Round in 2023
InContAlert is a deep tech start-up focused on improving the lives of individuals with bladder dysfunction through innovative medical technology. The company has developed an mHealth device that allows users to monitor the filling level of their urinary bladder without the need for catheters or frequent intervention from healthcare professionals. The device, which can be fastened using a belly band or clipped to underwear, features a sensor positioned just above the pubic bone to continuously measure bladder levels. This data is transmitted to an accompanying app, which alerts users when a predefined filling level is reached, thereby reducing the risk of uncontrolled urine loss and preventing harmful bladder distension. By leveraging deep learning algorithms for data analysis, InContAlert empowers incontinence patients to regain control and enjoy a more carefree lifestyle.
Doctorflix
Seed Round in 2023
Doctorflix is a medical education platform designed to enhance the professional development of healthcare providers worldwide. It offers a comprehensive array of resources, including on-demand videos, live events, articles, and podcasts, aimed at transforming theoretical knowledge into practical applications. The platform seeks to simplify and democratize access to medical knowledge by connecting doctors, hospitals, and pharmaceutical companies, thereby facilitating an efficient exchange of information. With a strong foundation in both medical and technological expertise, Doctorflix is dedicated to advancing the education of medical professionals, ensuring they stay informed about the latest treatment methods and practices.
smartbax
Seed Round in 2023
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Hema.to
Seed Round in 2023
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
Dualyx
Series A in 2023
Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.
Nia Health
Seed Round in 2023
Nia Health specializes in developing digital health applications that focus on dermatological conditions, particularly atopic dermatitis and psoriasis. The company utilizes an innovative MedTech platform to create personalized medical software that addresses the unique needs of each patient. Nia Health's AI-powered app offers tailored support and relief for individuals suffering from eczema, combining clinically validated content with features designed to enhance patient engagement. Originating from Charité Universitätsmedizin Berlin, the company aims to improve patient outcomes by providing effective treatments for chronic skin conditions while reducing the stigma associated with them. Nia Health has garnered significant funding, and its app is reimbursed by major health insurance providers in Germany.
Phialogics
Pre Seed Round in 2023
Phialogics is a preclinical biotechnology company that specializes in developing advanced biologics aimed at modulating the immune response in cases of acute and chronic inflammation. The firm focuses on creating cell therapies for the treatment of autoimmune diseases by employing protein engineering techniques to design cell-type-specific immune checkpoint activators. These innovations enable the production of signaling agonists that effectively influence the activity of immune cells, thereby assisting healthcare professionals in preventing multi-organ failure associated with autoimmune conditions.
Mosanna Therapeutics
Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel, focused on enhancing patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna selects innovative medicines for further development in collaboration with leading contract research organizations, ensuring that hospitals and healthcare providers have access to effective treatment options for patients suffering from various diseases. Through its targeted efforts, Mosanna aims to address significant healthcare challenges and improve therapeutic options for patients.
Mbiomics
Series A in 2023
Mbiomics is a biotechnology company focused on microbiome research, diagnostics, and therapeutics. It has developed a high-throughput, low-cost platform that allows for dynamic and real-time analysis and quantification of the human gut microbiome. By providing informed precision diagnostics and targeted therapies, Mbiomics aims to enhance patient outcomes and promote healthier living through innovative approaches.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
FundaMental Pharma
Seed Round in 2022
FundaMental Pharma is a neuroscience company focused on developing innovative treatments for neurological diseases at the preclinical stage. The company creates neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. Utilizing peptides and gene therapy, FundaMental Pharma specializes in diagnosing polymorphisms and is dedicated to developing a novel class of drugs that target untreatable neurological conditions. Through its research, the company seeks to provide pharmacological solutions for patients suffering from various challenging neurological disorders.
neotiv
Seed Round in 2022
Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.
Resolve BioSciences
Series B in 2022
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.
IRUBIS
Seed Round in 2022
IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.
KUPANDO
Series A in 2022
Kupando is a biopharmaceutical company focused on developing TLR 4/7 agonists to enhance innate immunity. The company aims to provide cancer patients with safe and affordable immunotherapy while also creating immunostimulatory drugs to prevent infectious diseases. By targeting toll-like receptors that detect cancer and infection markers, Kupando’s therapies activate the innate immune system, allowing healthcare providers to effectively treat both cancer and infectious diseases.
Aignostics
Series A in 2022
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
FaCellitate
Seed Round in 2022
FaCellitate is a developer of biomedical technology focused on enhancing cancer and stem cell research, along with drug discovery and toxicology. The company creates polymeric platforms that facilitate cellular interaction, significantly improving cell culture techniques in biological research. Their offerings include chemically defined, animal- and xeno-free cell culture coatings specifically designed for 3D cell culture and stem cell applications. These advanced lab surfaces provide researchers with the tools needed to conduct experiments more effectively, thereby advancing the fields of biomedical research and tissue engineering.
Kranus Health
Series A in 2022
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Noscendo
Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Ebenbuild
Seed Round in 2022
Ebenbuild is a health tech company that utilizes advanced research from TU Munich to develop a platform focused on respiratory diseases. The company offers a deep tech solution that includes two initial applications aimed at enhancing drug development and patient care. One application focuses on digital trials, enabling biotech and pharmaceutical companies to optimize drug delivery to the lungs through predictive models, thereby reducing risks and accelerating clinical development. The second application integrates with hospital IT systems to provide precise, actionable intelligence at the patient bedside, particularly for individuals with Acute Respiratory Distress Syndrome (ARDS). This technology personalizes mechanical ventilation settings, improving both short-term and long-term patient outcomes. By continuously expanding its platform to address various medical indications, Ebenbuild aims to deliver significant benefits to patients, healthcare providers, and payors.
Ceregate
Series A in 2022
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Emergence Therapeutics
Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.
Nebula Biocides
Seed Round in 2021
Nebula Biocides specializes in the development of innovative disinfection solutions aimed at effectively combating persistent bacterial spores and resistant viruses. The company focuses on creating application-oriented disinfection products that provide reliable protection against infections in various settings. Their offerings include advanced disinfection systems and devices designed to ensure comprehensive microbial control, addressing the challenges posed by stubborn pathogens. Through these solutions, Nebula Biocides aims to enhance health safety for users by delivering effective disinfection that can be utilized in diverse environments.
Abalos Therapeutics
Series A in 2021
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on developing innovative immuno-oncology therapeutics. Founded in 2019, the company specializes in arenavirus-based drug candidates aimed at stimulating immune responses to target primary tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's approach involves reprogramming the immune system to effectively identify and eliminate malignant tumor tissue, thereby offering potential new treatment options for cancer. Through its novel immuno-virotherapy, Abalos Therapeutics seeks to harness the full capabilities of the immune system specifically against cancer cells.
Qnami
Series A in 2021
Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.
PreComb
Seed Round in 2021
PreComb is a technology company focused on enhancing cancer treatment outcomes through innovative solutions tailored for difficult-to-treat cancers. The company has developed a 3D drug testing technology that utilizes automated microtumor-based profiling for in vitro cancer diagnosis. This technology enables clinical institutions to conduct on-site evaluations, allowing for the functional assessment of various cancer drugs, combinations, and concentrations using patient-derived micro-tumors. By optimizing the selection of therapies, PreComb aims to improve success rates in cancer treatment and ultimately enhance the quality of life for patients.
GeneQuine Biotherapeutics
Series A in 2021
GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.
Kranus Health
Seed Round in 2021
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Resolve BioSciences
Series A in 2020
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.
Synendos Therapeutics
Series A in 2020
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
heartbeat medical
Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Ceregate
Series A in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.
Aignostics
Seed Round in 2020
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
stimOS
Series A in 2020
stimOS GmbH, founded in 2015 and based in Constance, Germany, specializes in the development of innovative drug delivery systems that promote bone formation, anti-inflammatory responses, and healing processes. The company creates advanced technologies to refine, functionalize, and activate implant materials, transforming them into interfaces that closely mimic natural bone. By offering these technologies to implant manufacturers, stimOS supports the production of implants that enhance patient recovery and facilitate a pain-free post-surgical experience. Through its focus on research and development, stimOS aims to advance the field of implant technology and improve patient outcomes.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
NovaPump
Series A in 2020
NovaPump GmbH, based in Jena, Germany, specializes in the research, development, and distribution of non-invasive and percutaneous heart assist devices. Established in 2012, the company is focused on its innovative PERKAT technology, a self-expanding heart pump designed for acute left or right heart failure patients. This device will be available in the forms of pLVAD and pRVAD heart pumps, integrating with existing intra-aortic balloon pump techniques to enhance treatment options. The PERKAT system is notable for being catheter-based, pulsatile, and ECG-triggered, offering a cost-effective solution with high pump performance. Although the device is not yet on the market, it has been the subject of scientific publications and presentations at major cardiology conferences, highlighting its medical necessity and technological advantages. The company's mission is to provide timely and effective treatment for patients suffering from severe heart conditions, ultimately improving their chances of recovery.
Kumovis
Series A in 2020
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Noscendo
Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.
Scipio Bioscience
Series A in 2020
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
Ceregate
Venture Round in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.
HepaRegenix
Series B in 2020
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.
Mecuris
Series B in 2020
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.
Verovaccines
Seed Round in 2019
VEROVACCiNES GmbH is a biopharmaceutical company based in Halle, Germany, founded in 2017 as a spin-off from the Martin Luther University Halle-Wittenberg. The company specializes in developing innovative vaccine solutions to protect animals from infectious diseases, utilizing a unique yeast-based technology to create subunit marker vaccines. This approach has been validated through proof-of-concept studies demonstrating protection across various animal species against several viral diseases. VEROVACCiNES has acquired intellectual property, branding, and expertise from a previous project funded by the BMBF GO-Bio program and is eligible for additional funding. The company actively collaborates with veterinary pharmaceutical firms, universities, and research institutions to enhance its vaccine development efforts.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Qnami
Seed Round in 2019
Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.
Abalos Therapeutics
Series A in 2019
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on developing innovative immuno-oncology therapeutics. Founded in 2019, the company specializes in arenavirus-based drug candidates aimed at stimulating immune responses to target primary tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's approach involves reprogramming the immune system to effectively identify and eliminate malignant tumor tissue, thereby offering potential new treatment options for cancer. Through its novel immuno-virotherapy, Abalos Therapeutics seeks to harness the full capabilities of the immune system specifically against cancer cells.
Vacis
Venture Round in 2019
Vacis is a leading tissue engineering company focused on developing innovative solutions for vascular surgery. The company specializes in creating in situ tissue-engineered blood vessels, addressing a significant challenge in the field: the frequent failure of prosthetic vascular grafts, which often leads to complications and increased healthcare costs. Vacis's technology employs a synthetic rod with a specialized surface, which, when inserted under the skin, stimulates the body to form a tissue capsule that matures into a functional blood vessel. This process allows for the creation of autologous graft vessels that offer sustained patency and reduce the need for corrective interventions, ultimately providing patients with safer and more effective options for vascular access, particularly in hemodialysis.
Tacalyx
Seed Round in 2019
Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of Tumor-Associated Carbohydrate Antigens (TACAs) as innovative targets for cancer therapy. Originating as a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Tacalyx leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures are essential for generating and identifying antibodies aimed at developing new therapeutics. TACAs are characterized by their specific expression in tumors, which arises from abnormal glycosylation and is associated with promoting metastasis, angiogenesis, and immune system suppression. By combining sophisticated synthesis capabilities with comprehensive analysis and screening, Tacalyx aims to create novel immunotherapies that effectively stimulate anti-cancer responses.
Belyntic
Seed Round in 2019
Belyntic is a biotechnology company focused on developing innovative vaccines aimed at addressing viral diseases, bacterial infections, and cancer. The company has created a novel platform technology that produces self-adjuvant synthetic long peptides, which promote safe and durable cellular immunity. Belyntic offers ready-to-use research kits and engineered vaccines designed to activate T-cell immune responses, providing significant potential for the advancement of protective vaccines. Additionally, the company integrates artificial intelligence to predict pathogen-specific epitopes, enhancing the design of its self-adjuvant nano vaccine structures. This approach supports clients in the research, development, and production of novel peptide therapeutics, contributing to improved health outcomes.
miRdetect
Seed Round in 2019
miRdetect GmbH is a Bremen-based company that specializes in the development and marketing of in-vitro diagnostics for cancer detection. Founded in 2016, the company offers products such as miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect focuses on creating and manufacturing molecular biological tests that enable the early identification and diagnosis of various cancers by accurately detecting minute quantities of nucleic acids. In addition to its existing products, the company is actively engaged in research and development to expand its portfolio of diagnostic tests.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company focuses on developing and commercializing its proprietary NanoStraw platform technology, which facilitates direct access to the cytosol of cells. This innovative technology addresses a significant challenge in the field of cell and gene therapies by enabling the efficient and gentle delivery of various materials into difficult-to-transfect cells. Through its NanoStraw platform, NAVAN aims to enhance the capabilities of researchers in their efforts to advance therapeutic solutions.
Cytena
Series A in 2019
Cytena GmbH is a biotechnology company based in Freiburg, Germany, specializing in the development of laboratory devices for the separation and printing of single cells. Founded in 2014, the company offers innovative products such as the cy-Clone and a range of single-cell printing technologies, which are essential for applications in drug development and genetic analysis, particularly in cancer and stem cell research. The cy-Clone utilizes an automated imaging process to encapsulate single cells in droplets, ensuring their viability and preventing cross-contamination through the use of disposable components. Cytena's technology enables efficient and contact-free deposition of cells on various substrates, facilitating the analysis and growth of clonal colonies. With a distribution network that spans Europe, North America, India, Asia, and the United Kingdom, Cytena operates as a subsidiary of Cellink AB, enhancing the capabilities of researchers and developers in the life sciences sector.
Plasmion
Seed Round in 2019
Plasmion GmbH, founded in 2016 and based in Augsburg, Germany, specializes in the development of ionization devices for various scientific and industrial applications. The company's flagship product, the SICRIT SC-20X, includes a control unit and ion source, facilitating quality control in diverse fields such as food safety, medical diagnostics, security, forensics, and emission monitoring. Plasmion is at the forefront of innovative sensor technology, utilizing ambient mass spectrometry to enhance analytical capabilities in both laboratory settings and industrial process control. This technology aims to improve sensitivity and selectivity, addressing the limitations of traditional sensors and enabling real-time measurements in various applications. The company serves a global clientele through a network of sales partners, making significant strides in advancing the use of electronic nose technology.
Mecuris
Series A in 2019
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.
PreOmics
Series A in 2018
PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.
denovoMATRIX
Seed Round in 2018
denovoMATRIX GmbH specializes in the development and production of biomimetic coatings for stem cell culture, aiming to enhance cell manufacturing quality, quantity, and safety. Founded in 2018 and based in Dresden, Germany, the company offers products such as screenMATRIX, which facilitates various cellular functions including adhesion, differentiation, and organization, and myMATRIX, a custom-coated tissue cultureware designed for the growth of stem cells and primary cells in serum-free media. These innovative biomaterials are utilized in stem cell research, tissue modeling, and cell-based therapies, providing researchers with tailored solutions to address specific scientific inquiries and potential medical applications.
Amal Therapeutics
Series B in 2018
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
OMEICOS Therapeutics
Series C in 2018
OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Adivo
Seed Round in 2018
Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.
advanceCOR
Venture Round in 2018
advanceCOR GmbH is a drug development company based in Munich, Germany, specializing in therapeutics and diagnostics for heart and vascular diseases. Founded in 2000, the company focuses on creating personalized treatments and has developed several innovative products. Notable among these is Revacept, a human Fc fusion protein that inhibits the local activation of platelets at vascular injury sites. Additionally, advanceCOR offers COR-2, a recombinant protein that reduces foam cell generation and cholesterol uptake, and COR-3, which targets atherosclerotic plaques while binding to progenitor cells to promote plaque healing. The company’s product pipeline also includes therapies for acute arterial thrombosis, myocardial infarction, stroke, and transient ischemic attack, emphasizing its commitment to addressing serious cardiovascular conditions.
Newsenselab (M-sense)
Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
neotiv
Seed Round in 2018
Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.
heartbeat medical
Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Scipio Bioscience
Seed Round in 2017
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
RIMASYS
Venture Round in 2017
RIMASYS is dedicated to advancing surgical education and medical technology research and development. The company focuses on creating realistic fractures in human specimens through a unique algorithm and device, which supports practical skill training for surgeons. By integrating digital learning, virtual reality, and 3D printing, RIMASYS aims to improve patient outcomes and enhance the quality of life for individuals requiring advanced therapies and operations. Their innovative approach facilitates collaboration among medical science, academia, and industry, fostering the development of better implants and surgical techniques.
Amal Therapeutics
Series B in 2017
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
stimOS
Seed Round in 2017
stimOS GmbH, founded in 2015 and based in Constance, Germany, specializes in the development of innovative drug delivery systems that promote bone formation, anti-inflammatory responses, and healing processes. The company creates advanced technologies to refine, functionalize, and activate implant materials, transforming them into interfaces that closely mimic natural bone. By offering these technologies to implant manufacturers, stimOS supports the production of implants that enhance patient recovery and facilitate a pain-free post-surgical experience. Through its focus on research and development, stimOS aims to advance the field of implant technology and improve patient outcomes.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, established in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays aimed at diagnosing infectious diseases and cancer. The company utilizes isothermal amplification technology to create rapid tests that enable healthcare professionals to make timely diagnoses, often within 30 minutes, thereby facilitating prompt treatment decisions. In addition to its diagnostic assays, KSK Diagnostics offers customizable services, including the development of nucleic acid-based tests using real-time PCR or RT-PCR, as well as verification and validation studies and product enhancement services for other organizations in the healthcare sector. As a pioneer in this field, KSK Diagnostics is dedicated to improving patient-oriented diagnostics through innovative technologies.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotech company focused on the preclinical and early clinical development of novel biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Founded in 2016 through collaboration between academic and industry scientists with expertise in antibody development, SciRhom leverages extensive research and a network of specialists to advance its therapeutic offerings. The company develops therapeutic antibodies targeting iRhom2, a significant modulator of key pro-inflammatory signaling pathways, including TNF-alpha. This approach seeks to enhance treatment options for patients suffering from severe autoimmune conditions, particularly those affecting the skin and intestinal barriers.
HepaRegenix
Series A in 2016
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.
Whitesonic
Seed Round in 2016
Whitesonic is a company focused on developing an ultrasound-based scanner for the field of digital dentistry. This innovative scanner captures detailed impressions of dental structures non-invasively and without radiation, utilizing high-frequency acoustic waves. The technology enables dentists to efficiently record and prepare essential dental data and soft tissue information. As of 2017, a prototype of the scanner was available for patient use, with plans to obtain medical product approval following an evaluation phase. Through these advancements, Whitesonic aims to enhance dental practices and improve patient outcomes in dental care.
AudioCure Pharma
Series A in 2016
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, focused on developing treatments for hearing impairments and neurodegenerative diseases. Founded in 2012 by Professor Hans Rommelspacher, a clinician and academic, the company is supported by a team of skilled scientists and executives, alongside a network of academic partners and strategic investors. AudioCure’s operations are strategically located in Mitte, providing access to Berlin's vibrant tech and academic scene, including close ties with Charité University, which facilitates collaboration with leading experts. The company is advancing its lead compound, AC102, which is in late-stage preclinical development for acute noise-induced hearing loss, having achieved preclinical proof of concept in 2016.
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Mecuris
Seed Round in 2016
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of custom orthopedic aids, including orthoses and prostheses. The company empowers orthopedic and prosthetic (O&P) professionals through its Mecuris Solution Platform, which integrates digital technology and 3D printing. This platform allows for the co-creation of individualized O&P products by utilizing patient data and scans to semi-automatically generate custom 3D designs. These designs can be printed locally, ensuring a tailored fit and reducing production times by up to 75%. Mecuris aims to enhance the lives of wearers by providing quick, personalized solutions that meet their specific needs.
Immunic Therapeutics
Series A in 2016
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Bentekk
Seed Round in 2016
Bentekk GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development and manufacture of intelligent gas measuring systems aimed at on-site analysis of contaminants. The company produces portable gas measurement devices that utilize gas chromatography and photo ionization detection for the assessment of volatile organic compounds, including hazardous substances like benzene. These devices are designed to enhance occupational health and safety across various sectors, including environmental monitoring, emergency response, logistics, life sciences, and the chemical industry. By providing accurate and rapid measurements of toxic gases, Bentekk supports improved safety and compliance with threshold limit values, contributing to a safer working environment. As of April 2017, Bentekk operates as a subsidiary of Dräger Safety AG & Co. KGaA.
Amal Therapeutics
Series A in 2016
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
SeNostic Health GmbH
Seed Round in 2016
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.
Abviris Deutschland
Seed Round in 2016
Abviris Deutschland GmbH is a German company specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Founded in 2014 and based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies and antigens targeting different strains of human papilloma virus (HPV), which is a significant risk factor for oral cancer. One of its key products is PrevO-Check, an in-vitro diagnostic device designed to screen for HPV-induced oral cavity cancers. The company addresses a critical need in early detection, as HPV infections often present no early symptoms, leading to late-stage diagnoses when lesions are finally identified.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.